Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-ADSC-01 for Spinocerebellar Ataxia (SCA3/SCA6)
jRCT2043190090Active, not recruiting
- Sponsor
- REPROCELL
- Start
- Jul 2020
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
Randomised, double-blind trial in machado-joseph disease (MJD) and spinocerebellar ataxia type 6 (SCA6) comparing SB-ADSC-01 with Placebo (2 arms). Primary endpoint: Primary - Change in SARA score to Week 52. Started Jul 2020; status: active, not recruiting.
02
Drugs
SB-ADSC-01
03
Conditions
machado-joseph disease (MJD)spinocerebellar ataxia type 6 (SCA6)
Beyond the preview
Go deeper on jRCT2043190090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043190090.